Diagnosis and treatment of DVT and prevention of DVT recurrence and the PTS: bridging the gap between DVT and PTS in the primary care setting or outpatient ward

Jan Jacques Michiels1–3
Wim Moosdorff1
Mildred U Lao1
Hanny Maasland1
Janneke Maria Michiels2,4
HA Martino Neumann5
Petra Dulicek6
Viera Srvtinová3,7
Pavel Poredos3,8
Jacques Barth1,3
Gualtiero Palareti1,9

1 Primary Care Medicine Medical Diagnostic Center, Rotterdam, 2 Goodheart Institute, Blood Coagulation and Vascular Medicine Science Center, Rotterdam, the Netherlands; 3 Central European Vascular Forum, Prague, Czech Republic; 4 Primary Care Medicine, Leiden University Medical Center, Leiden; 5 Department of Dermatology, Section Phlebology, Erasmus University Medical Center, Rotterdam, the Netherlands; 6 4th Department of Internal Medicine – Hematology, University Hospital in Hradec Kralove and Charles University in Prague, Faculty of Medicine, Hradec Kralove, Czech Republic; 7 Internal Medicine Medical Faculty, Comenius University, Bratislava, Slovakia; 8 University Medical Centre Ljubljana, Department of Vascular Disease, Ljubljana, Slovenia; 9 Department of Angiology and Blood Coagulation, University Hospital, Bologna, Italy

Abstract: Duplex ultrasonography (DUS) does pick up alternative diagnoses (AD) including Baker’s cyst, muscle hematomas, old deep vein thrombosis (DVT), and superficial vein thrombosis. The sequential use of DUS followed by a sensitive D-dimer test and a clinical score assessment is a safe and effective noninvasive strategy to exclude and diagnose DVT and AD in patients with suspected DVT. DVT patients are recommended to wear medical elastic stockings (MECS) for symptomatic relief of swollen legs during the acute phase of DVT, or when postthrombotic syndrome (PTS) is present. In routine daily practice, discontinuation of anticoagulation at 6 months post-DVT is followed by a subsequent 20%–30% DVT recurrence rate; this is the main cause of PTS after 1–5 years of follow-up. To bridge the gap between DVT and PTS, the frequent occurrence of PTS is best prevented by prolonged anticoagulation, if indicated, based on objective risk factors for DVT recurrence. Post-DVT rapid and complete recanalization on DUS within 1–3 months and no reflux is associated with no development of PTS, obviating the need of MECS; furthermore, anticoagulation can be discontinued after 3–6 months post-DVT. Absence of residual venous thrombosis (complete recanalization) at 3 months post-DVT with no reflux and with a low PTS score is associated with no recurrence of DVT (1.2% of 100 patient/years). The presence of reflux due to valve destruction, irrespective of the degree of recanalization on DUS at 3–6 months post-DVT, is associated with a high risk of DVT recurrence and symptomatic PTS, indicating the need to wear MECS and extend anticoagulation. Appearance of reflux on DUS at 6 months or 9 months post-DVT in symptomatic PTS patients is associated with increased DVT recurrence in about one-third of post-DVT patients after the discontinuation of anticoagulation. We designed a prospective safety outcome management study to bridge the gap between DVT and PTS, with the aim of reducing the overall DVT recurrence rate to <3% patient/years during long-term follow-up.

Keywords: deep vein thrombosis, DVT recurrence, postthrombotic syndrome, D-dimer, clinical score

Deep vein thrombosis (DVT) and alternative diagnoses mimicking DVT

Symptomatic DVT or calf vein thrombosis may be the tip of a “clotted iceberg”. The cause of DVT may be idiopathic or provoked, usually in the context of surgery, trauma, pregnancy, and during the postpartum period. Alternative diagnoses (AD) like Baker’s cyst, ruptured Baker’s cyst, torn plantaris tendon, hematoma,
muscle tears or pulls, erysipelas, lymphedema, and so on, should also be differentiated from DVT. Accurate differentiation between AD and DVT, or the absence of both, in outpatients with suspected DVT by a clinical assessment according to the Wells scores is subjective; it depends on experienced supervision by highly specialized clinicians in carefully controlled clinical settings, and it does not appear to be reproducible in multidisciplinary settings in hospitals or in multicenter clinical trials. Consequently, in 1998, we decided to eliminate the “score of minus 2” for AD. In our prospective DVT management study of more than 2,000 outpatients with suspected DVT, patients were referred to our medical diagnostic center in Rotterdam (the Netherlands) between 2005 and 2012 to exclude or diagnose DVT and AD (Figure 1). In our DVT studies, we used the Rotterdam modification of the Wells clinical score assessment as a fill-in form at the time of DVT and AD exclusion and diagnosis in the setting of a medical diagnostic laboratory in the primary care setting (which is equivalent to the outpatient hospital setting). The “AD minus 2” scoring procedure is subjective, not specific, not sensitive, and not reproducible enough in daily clinical hospital and outpatient practice, and it should not be used in daily clinical and outpatient practice.

The advantage of complete duplex ultrasonography (CDUS) of the calf, popliteal, femoral, and iliac veins is that it does pick up distal and proximal DVT and AD, such as Baker’s cysts, muscle hematomas, old DVTs, and superficial vein thrombosis (SVT). AD with a negative duplex ultrasonography (DUS) include leg edema, varices, erysipelas, and so on. The NPV of CDUS by experienced specialists was 99.5% in the medical diagnostic laboratory setting or outpatient ward in three large management studies with a prevalence of DVT from 14%–33%. CDUS in a prospective clinical study of 623 patients with suspected DVT detected AD in a total of 248 cases (60.5%). An underlying disease and abnormal CDUS was found in 172 (42%) cases, with venous reflux in 93, muscular lesions in 20, hematoma in 24, and Baker’s cyst in 35 (eight ruptured). In addition, an underlying disease and normal DUS was found in 77 (18.5%) cases, including peripheral artery disease, cutaneous infection, neurologic/rheumatologic disease, and lymphedema. These clinical observations indicate that CDUS is far superior to phlebography and should become

---

**Figure 1** The Rotterdam strategy to safely exclude and diagnose DVT and AD with a sensitivity and specificity near 100% by the sequential use of CUS, DD, and clinical score assessment.

**Note:** VIDAS® (BioMerieux, Lyon, France).

**Abbreviations:** CUS, compression ultrasonography; ELISA, enzyme-linked immunosorbent assay; DD, D-dimer; neg, negative; DVT, deep vein thrombosis; AD, alternative diagnosis.
the first objective step for the diagnosis and exclusion of DVT and AD.

**Sequential DUS, D-dimer, and clinical score**

Based on personal experiences and evidence-based objective diagnostic tools, in 2005 we developed the Rotterdam concept (Figure 1) to safely exclude and diagnose DVT, as per the following reasoning. First, a negative CDUS and a negative enzyme-linked immunosorbent assay (ELISA) D-dimer (VIDAS® [BioMerieux, Lyon, France] <500 ng/mL) test excluded DVT with a sensitivity and specificity near 100%, irrespective of the clinical score assessment. After a first negative CDUS, the prevalence of DVT in routine daily practice is uniformly low at 2%–3%. The combination of a negative qualitative D-dimer test (SimpliRED or Simplify) and low clinical score should be estimated as not being safe enough, mainly because the prevalence of DVT in the low clinical score group may vary widely (3%–12%). The safest, most effective, and sensitive approach to determine DVT and AD exclusion is to start with objective testing via CDUS, followed by a sensitive D-dimer test without the use of or need for clinical score assessments (Figure 1). A first negative CDUS and a negative sensitive D-dimer test (ELISA VIDAS <500 ug/mL) excludes DVT, irrespective of the clinical score assessment (left arm; Figure 1). The combination of a first negative compression ultrasonography (CUS), a low clinical score with a VIDAS D-dimer level of <1,000 ug/mL, a Tina-quant® (Hoffman-La Roche Ltd, Basel, Switzerland) level <800 ug/mL, or a negative SimpliRED or Simplify test safely excluded DVT with an NPV of near to 100% in four prospective outcome studies (middle arm; Figure 1). Those patients with a clear suspicion of DVT with a moderate to high Rotterdam clinical score and with pronounced increased D-dimer levels (VIDAS >1,000 ug/mL; Tina-quant >800 ug/mL) or a positive qualitative D-dimer SimpliRED or Simplify test are candidates for a repeated DUS of the legs after 1 week (right arm; Figure 1). The Rotterdam concept in Figure 1 is under investigation in two prospective management studies of more than 2,000 patients, which were conducted in the period between 2006–2012 (Michiels et al unpublished data 2014).

**DVT recurrence related to normal or abnormal CUS at 3 months post-DVT**

In a study by Siragusa et al., residual vein thrombosis (RVT) was detected in 180 (69.8%) of 258 DVT patients at 3 months post-DVT. In the cohort of 78 patients who underwent rapid recanalization within 90 days (3 months), anticoagulation was discontinued at 3 months post-DVT; the risk of recurrent venous thromboembolism (VTE) during follow-up was 1.3% (95% confidence interval [CI], 1%–7%; Table 1). The proportion of provoked versus unprovoked DVT was 64% and 36%, respectively. The group of 180 DVT patients with RVT (with or no partial recanalization on DUS) were randomized to stop anticoagulation at 3 months post-DVT and in 17 of 88 (20%) or to continue the anticoagulant for 9 additional months, while discontinuing it 12 months post-DVT. During follow-up, from the time that the anticoagulant was discontinued, recurrent VTE events occurred in 25 of 92 (25%) versus RVT after discontinuance of anticoagulation at 3 months post-DVT and, respectively, after discontinuance of anticoagulation at 12 months post-DVT (Figure 2). Interestingly, the proportion of provoked versus unprovoked DVT in patients with residual vein occlusion (RVO) (incomplete recanalization) at 3 months post-DVT was 3% versus 77%, respectively, again indicating that this distinction is artificial in terms of its risk on DVT recurrence.

In the extended DACUS study 409 patients with a first unprovoked DVT were evaluated for the presence of residual vein thrombosis (RVT) at 3 months post-DVT. DVT patients without RVT suspended VKA after 3 months, while those with RVT continued oral anticoagulation for up to 2 years.

**Table 1** DVT recurrence is related to normal CUS at 3 months post-DVT (rapid recanalization) versus abnormal CUS at 3 months post-DVT (delayed recanalization) in the DACUS and extended DACUS Studies.

<table>
<thead>
<tr>
<th>DCUS study CUS at 3 months post-DVT</th>
<th>CUS Normal no RVT</th>
<th>CUS Abnormal RVT</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>78</td>
<td>180</td>
<td></td>
</tr>
<tr>
<td>Provoked DVT</td>
<td>50 (64%)</td>
<td>44 (24%)</td>
<td></td>
</tr>
<tr>
<td>Idiopathic DVT</td>
<td>28 (36%)</td>
<td>138 (76%)</td>
<td></td>
</tr>
<tr>
<td>DVT recurrence after discontinuation of VKA (3 year follow-up)</td>
<td>1 (1.3%)</td>
<td>42 (23%)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extended DACUS study CUS at 3 months post-DVT</th>
<th>No RVT</th>
<th>RVT</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>136</td>
<td>258</td>
<td></td>
</tr>
<tr>
<td>VTE recurrence after discontinuation of VKA</td>
<td>2 (1.4%)</td>
<td>27 (10.4%)</td>
<td>0.0026</td>
</tr>
<tr>
<td>VTE recurrences % per 100 person-years</td>
<td>1.4%</td>
<td>10.4%</td>
<td>0.022</td>
</tr>
</tbody>
</table>

**Abbreviations:** RVT, residual vein thrombosis; DACUS, Duration of Anticoagulation based on Compression Ultrasonography Study; VKA: vitamin K antagonist; VTE, venous thromboembolism; CUS, compression ultrasonography; DVT, deep vein thrombosis.
Among 409 patients evaluated for unprovoked DVT, 33.2% (136 of 409 patients) did not have RVT and VKA was stopped after 3 months. The remaining 273 (66.8%) patients with RVT received anticoagulants for an additional 21 months; during this period of treatment, recurrent venous thromboembolism and major bleeding occurred in 4.7% and 1.1% of patients, respectively. However, after VKA suspension, the rates of recurrent thrombotic events were 1.4% in the no-RVT group and 10.4% in the RVT group (relative risk = 7.4; 95% confidence interval = 4.9–9.9). These results indicate that in patients without RVT, a short period of treatment with a VKA is sufficient; in those with persistent RVT, treatment extended to 2 years substantially reduces, but does not eliminate, the risk of recurrent DVT.

### The postthrombotic syndrome (PTS)

The Clinical–Etiology–Anatomic–Pathophysiological (CEAP) classification for PTS is well known and widely applied by phlebologists. The simplified CEAP classification for PTS is not used by clinicians or vascular medicine specialists (Table 2). In 1992, Prandoni developed an original standardized scale for the assessment of PTS in post-DVT legs (Paolo Prandoni, Institute of Medical Semeiotics, University Hospital of Padua, Italy; personal communication). Each subjective sign and objective symptom was scored as 0, 1, 2, or 3 based on clinical judgment. The five signs and seven symptoms of the original Prandoni score are taken over by PTS investigators as the Villalta in the literature. The Prandoni subjective signs and objective symptoms (Villalta score) have never been evaluated against the objective CEAP scoring system (Tables 2 and 3). It is mandatory that the Prandoni (Villalta) scoring system of the subjective signs and objective symptoms of early PTS be verified against the objective CEAP scoring system in Tables 2 and 3 at 3 months, 6 months, and 12 months post-DVT up to 2–5 years post-DVT in prospective management studies. This statement is of particular interest, since the data from the literature are convincing in showing that PTS is present in about 50% of post-DVT patients at 1 year post-DVT using the Villalta score and are not compared with the CEAP score.

### DVT recurrence and PTS

In a post hoc analysis of a selected large group of 452 patients with unprovoked DVT (Table 2), Le Gal et al performed a study of

### Table 2 Simplified clinical part of the CEAP classification for the severity of chronic venous insufficiency (either primary or secondary)12

<table>
<thead>
<tr>
<th>Classification</th>
<th>Symptom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical: C</td>
<td></td>
</tr>
<tr>
<td>C0 asymptomatic</td>
<td>No visible varicose veins</td>
</tr>
<tr>
<td>C1</td>
<td>Spider or reticular veins</td>
</tr>
<tr>
<td>C2</td>
<td>Varicose veins</td>
</tr>
<tr>
<td>C3</td>
<td>Edema</td>
</tr>
<tr>
<td>C4a</td>
<td>Pigmentation or eczema</td>
</tr>
<tr>
<td>C4b</td>
<td>Lipodermatosclerosis or atrophy blanche</td>
</tr>
<tr>
<td>C5</td>
<td>Skin changes with healed ulceration</td>
</tr>
<tr>
<td>C6</td>
<td>Skin changes with active ulceration</td>
</tr>
</tbody>
</table>

### Table 3 Interpretation of the clinical scoring system according to Prandoni for the assessment of early PTS in the early period of 3–12 months post-DVT, up to 2 years post-DVT

<table>
<thead>
<tr>
<th>Five subjective symp: identical to symp of CEAP</th>
<th>Seven objective signs</th>
<th>All belong to C of CEAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heaviness of the foot/leg</td>
<td>Pretibial edema</td>
<td>C3</td>
</tr>
<tr>
<td>Pain in the calf/thigh</td>
<td>Induration of the skin</td>
<td>C4</td>
</tr>
<tr>
<td>Cramps in the calf/thigh</td>
<td>Hyperpigmentation</td>
<td>C4</td>
</tr>
<tr>
<td>Pruritis</td>
<td>New venous ecstasia</td>
<td>C2</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>Redness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pain during calf compression (post-DVT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ulceration of the skin</td>
<td>CS, C6</td>
</tr>
</tbody>
</table>

### Notes:
Each sign or symptom is graded with a score of 1, 2, or 3 (1 = mild; 2 = moderate; 3 = severe). Ulceration of the skin is 4 points. The presence of a leg ulcer is a late complication of PTS, consistent with severe CIV (CEAP 5, CEAP 6). Definition of clinical PTS according to Prandoni (Villalta): absent, score ≤5; mild to moderate, score between 5–10 and 10–15, respectively, at two consecutive visits; severe, score ≥15 on two consecutive occasions. Conclusion: the Prandoni or Villalta scoring system for PTS is a combination of subjective signs and complaints of PTS and evaluation of objective leg swelling and skin lesions according to the CEAP classification by an internist without expert dermatological evaluation and objective testing with CUS. Moreover, this scoring system should be used at 1 month, 3 months, 6 months, 9 months, and 1 year post-DVT for the assessment of the disappearance or persistence of DVT symptoms and the appearance of mild, moderate, and severe PTS symptoms.

### Abbreviations:
PTS, postthrombotic syndrome; DVT, deep vein thrombosis; CEAP, Clinical–Etiology–Anatomic–Pathophysiological; C, clinical; CIV, chronic venous insufficiency; CUS, compression ultrasonography; symp, symptoms.
DUS at 6 months if the post-DVT patient had signs or symptoms 5–7 months post-DVT, when the oral anticoagulation (OAT) was stopped. In the study by LE Gal et al, overt PTS was present in 184 of 452 (46%) cases, with symptoms of hyperpigmentation (CEAP ≥4), edema (CEAP >3), or redness in either leg (Table 2). Recanalization on DUS was complete in 220 patients and abnormal in 231 patients, with minimal wall thickening in eleven, partial thrombus resolution in 78, minimal thrombus resolution (obstruction) in 23, and missing data in 67, but reflux was not measured. During the follow-up period (once patients were off the OAT), 45 of 231 patients with abnormal CUS (19.5%) and 32 out of 220 patients (14.6%) with normal DUS (complete recanalization) had recurrent VTE. The conclusion is that the degree of recanalization (complete versus incomplete) alone at 6 months post-DVT is not predictive of DVT recurrence and the presence or development of PTS.

Rodger et al and Verhovsek et al conducted a multicenter, prospective cohort clinical decision rule derivation of 646 patients with a first unprovoked VTE treated with OAT for about 6 months; patients were followed for recurrent VTE after OAT discontinuation. PTS signs, as assessed by the presence of hyperpigmentation, edema, and redness (HER), appeared to make biological and clinical sense as important risk factors for DVT recurrence and the onset of embolic complications. The presence of HER as can be quantified by the Villalta scoring system (defined by Prandoni), as used by clinicians, and/or by objective CEAP criteria used by phlebologists—e.g., at normal dimer levels—after the discontinuation of OAT, irrespective of CUS abnormalities at 6 months to 12 months post-DVT are predicted to become the strongest predictors of DVT recurrence as the cause of PTS development or progression.

### Clinical features of PTS

A Dutch study conducted in 2004 prospectively evaluated the incidence and severity of PTS in 93 DVT patients under careful clinical surveillance using the CEAP classification (Figure 2). This study confirmed the findings from previous studies, whereby only half of DVT patients had no clear evidence of PTS (CEAP 0/1 and CEAP 2; Figure 2). In this study, the cumulative incidence of PTS (CEAP 3 and CEAP 4) increased from 49% after 1 year to 55% and 56% after 2 years and 6 years, respectively. Class C5 (active ulceration) and C6 (healed ulcers) did not occur while on long-term treatment with medical elastic stockings (MECS) (Figure 2).

Aschwanden et al studied the effect of prolonged treatment with MECS to prevent PTS in a randomized clinical trial (patients were recruited between 1997 and 2004 comparing intervention with no intervention [control] in case of mild PTS [CEAP 1 and 2]). In this study, DVT patients completed the recommended anticoagulation treatment with low molecular weight heparin followed by a vitamin K agonist (VKA) for 6 months. The inclusion criteria at 6 months post-DVT were early PTS with CEAP C0/1, CEAP C2, or CEAP C3 without skin lesions, and the exclusion criteria were CEAP C4–C6 with skin lesions. The primary end point was defined as a progression of PTS (CEAP C1–C3) without skin lesions to PTS with skin changes (CEAP C4 or higher). The intention-to-treat population consisted of 169 patients. The incidence and distribution of the post-thrombotic syndrome (PTS) according to the CEAP classification (Table 3) during long-term follow-up. The completeness of follow-up was 85% in the intervention group and 75% in the control group, with a mean follow-up of 3.2 years in the intervention group and 2.9 years in the control group. The secondary end point was independently evaluated and defined by the presence of five PTS-associated symptoms, according to Widmer: pain; heaviness; sensation of heat; tension; and tiredness of the affected limb. Overall, the primary end point (CEAP ≥4 or higher; skin lesions) developed in 13% of the intervention group and 20% of the control group. The secondary end point of at least one of the five Widmer symptoms was recorded in 12.2% of follow-up visits in the intervention group and 16.5% of follow-up visits in the control group. Recurrent DVT and female sex were major risk factors for the development of PTS (≥C4 or higher; skin lesions) after 2–6 years’ follow-up in patients with reflux and/or obstruction on DUS at the time of inclusion, at 6 months post-DVT.

### Pathophysiology and objective monitoring of PTS

Meissner et al studied the relationship between time to complete recanalization post-DVT (lysis time of the leg vein clot) and the development of reflux in patients with a first episode of DVT at 3-month intervals during the first year (Figure 3). Duplex criteria for complete occlusion were defined as the absence of detectable flow, either spontaneous or with augmentation, in an incompressible venous segment. Partial occlusion was defined as normal or diminished flow, either spontaneous or with augmentation, in an incompletely compressible venous segment. Complete lysis of the leg vein clot (recanalization) was presumed to have occurred when spontaneous phasic flow returned and the vein was completely compressible. For the posterior tibial veins, flow detected after distal augmentation in a completely compressible vein is accepted as evidence of complete recanalization (lysis of
the leg vein clot). The DVT–Lysis–Reflux Study\textsuperscript{23} in Figure 3 shows that a rapid and short leg clot lysis time (in terms of complete recanalization of the DVT within 1–3 months; lysis time 65–130 days) is associated with no development of reflux; patients usually have no PTS, and they do not need to continue the use of MECS 3 months post-DVT. This accounts for about two-thirds of patients with a first event of DVT. The DVT patients with rapid recanalization (lysis time) within 3 months post-DVT had calf or popliteal vein thrombosis at diagnosis in 68 of 118 (58%), and proximal femoral vein thrombosis in 46 of 118 (40%) DVT patients. The majority of DVT patients with delayed recanalization and reflux had proximal femoral DVT (42 of 52 patients and popliteal DVT in 10 of 52 DVT patients).\textsuperscript{23}

Notes: A rapid recanalization of thrombosed legs in DVT patients within 3 months (median thrombosisis lysis time from DVT to complete recanalization in 100 days; striped bars) in 118 post-DVT patients was associated with no reflux in all segments (striped bars). These DVT patients with rapid recanalization had popliteal or distal DVT in 68 of 118 and proximal femoral DVT in 46 of 118. A delayed recanalization of thrombosed legs in DVT patients (median thrombosisis lysis time from DVT to the complete recanalization of all vein segments of >6 months to about 9–12 months [black bars]) in 65 DVT patients was associated with the development of reflux as the main determinant of symptomatic PTS (black bars). The majority of DVT patients with delayed recanalization and reflux had proximal femoral DVT in 42 of 52 patients and popliteal DVT in 10 of 52 DVT patients.\textsuperscript{23}

Abbreviations: CFV, common femoral vein; SFP, superficial femoral vein; SFD, distal superficial vein; PPV, popliteal vein; PTV, posterior tibial vein; SFM, middle superficial femoral vein; SFD, distal superficial vein; PTV, posterior tibial vein; PV, popliteal vein; GSV, greater saphenous vein; DVT, deep vein thrombosis; PTS, postthrombotic syndrome.

As shown in Figure 4, reflux due to a loss of valve competence leading to ambulatory venous hypertension and diversion of venous flow through incompetent perforator veins appear to play an important role in the development of the late complications of PTS.\textsuperscript{24} In this study of 123 legs with DVT (107 patients), about two-thirds of the involved legs had developed valve incompetence.\textsuperscript{24} The distribution of reflux at the end of the first year follow-up study was the following: popliteal vein, 58%; femoral vein, 37%; greater saphenous vein, 25%; and posterior tibial vein, 18%. Reflux appeared

Figure 3 Rapid recanalization of thrombosed legs in DVT patients.

Notes: A rapid recanalization of thrombosed legs in DVT patients within 3 months (median thrombosisis lysis time from DVT to complete recanalization in 100 days; striped bars) in 118 post-DVT patients was associated with no reflux in all segments (striped bars). These DVT patients with rapid recanalization had popliteal or distal DVT in 68 of 118 and proximal femoral DVT in 46 of 118. A delayed recanalization of thrombosed legs in DVT patients (median thrombosisis lysis time from DVT to the complete recanalization of all vein segments of >6 months to about 9–12 months [black bars]) in 65 DVT patients was associated with the development of reflux as the main determinant of symptomatic PTS (black bars). The majority of DVT patients with delayed recanalization and reflux had proximal femoral DVT in 42 of 52 patients and popliteal DVT in 10 of 52 DVT patients.\textsuperscript{23}

Abbreviations: CFV, common femoral vein; SFP, superficial femoral vein; SFD, distal superficial vein; SFM, middle superficial femoral vein; SFD, distal superficial vein; PTV, posterior tibial vein; PFV, popliteal vein; PT, posterior tibial vein; PV, popliteal vein; GSV, greater saphenous vein; DVT, deep vein thrombosis; PTS, postthrombotic syndrome.

Figure 4 (A,B) Localization and incidence of reflux in deep veins in post-DVT patients who developed reflux on DUS at the different follow-up intervals post-DVT.

Notes: Follow-up intervals were as follows: 1 day; 1 week; 1 month; 3 months; 6 months; 9 months; 1 year; 2 years; and 3 years in the 1993 landmark Leg Thrombosis Lysis–Reflux study. Courtesy of Dr Markel, International Union of Angiology; IJA.

Abbreviations: DVT, deep vein thrombosis; DUS, duplex ultrasonography.
to be more frequent in the segments previously affected by femoral DVT. In retrospective, these data are completely in line with those from the studies of Siragusa et al, Le Gal et al, and Aschwanden et al. At 3 months post-DVT, complete recanalization and the absence of PTS (normal DUS) will predict a low risk of DVT recurrence. With respect to delayed recanalization of more than 3 months to about 6–12 months post-DVT, complete or nearly complete recanalization is associated with significant reflux, mild to moderate PTS (CEAP 1–3), or overt PTS (CEAP ≥4). This group of post-DVT patients has been predicted to be at high risk of DVT recurrence.

Medical elastic stockings (MECS) and PTS

Two prospective research studies on the use of MECS in acute DVT that complete recanalization within 3–6 months and no reflux is associated with no PTS, obviating the need for MECS 6 months after DVT (Rotterdam score =0 at 6 months; Table 4); half of patients with a first DVT do not need MECS. On the other hand, partial and complete recanalization after 6 months to more than 12 months is usually complicated by reflux due to valve destruction (Rotterdam score =3 or higher; Table 4). The incidence of asymptomatic PTS in the control arm of two randomized clinical trials was about 50% within 6 months, and this did not significantly increase thereafter (Rotterdam score =0 at 6 months; Table 4), obviating the need to wear MECS.

Table 4 Proposed objective Rotterdam score as derived from eight prospective studies for DVT recurrence risk assessment at 6–12 months post-DVT

<table>
<thead>
<tr>
<th>Objective score</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single vein segment isolated (IDVT)</td>
<td>1</td>
</tr>
<tr>
<td>Extended multiple site (EDVT)</td>
<td>3</td>
</tr>
<tr>
<td>Complete recanalization at 3 months and no reflex</td>
<td>0</td>
</tr>
<tr>
<td>No or incomplete recanalization at 6 months and no reflux</td>
<td>2</td>
</tr>
<tr>
<td>Complete recanalization after 6 months and reflux</td>
<td>3</td>
</tr>
<tr>
<td>Incomplete recanalization after 3 months and reflux</td>
<td>3</td>
</tr>
<tr>
<td>Obstruction after 1 year without or with reflux</td>
<td>4</td>
</tr>
<tr>
<td>Normal D-dimer levels after discontinuation of anticoagulant therapy</td>
<td>0</td>
</tr>
<tr>
<td>Increased D-dimer levels after discontinuation of anticoagulant therapy</td>
<td>3</td>
</tr>
<tr>
<td>CEAP 2, 3, 4 at ≥6 months post-DVT</td>
<td>2, 3, and 4, respectively</td>
</tr>
</tbody>
</table>

Notes: Score of ≤2, discontinuation of MECS and anticoagulation; score of ≥3, extend MECS if PTS is present, and prolong anticoagulation according to the PROLONG D-dimer strategy.

Abbreviations: CEAP, Clinical-Etiology-Anatomic-Pathophysiological; DVT, deep vein thrombosis; IDVT, isolated deep vein thrombosis; EDVT, extended deep vein thrombosis; MECS, medical elastic stockings; PTS, postthrombotic syndrome; PROLONG, prolonged anticoagulation.

Dovepress

MECS decreased the incidence of PTS symptoms (in terms of the Villalta clinical score) from around 50%–25% during a 2-year follow-up in the Brandjes and Prandoni studies. The main disadvantage of the Brandjes and Prandoni studies is that they did not measure PTS objectively by the CEAP score and DUS. It can be predicted that complete recanalization and no reflux at 3–6 months post-DVT will be associated with no PTS, obviating the need to continue to wear MECS (Figures 5 and 6).

In the study by Labropoulos et al, half of the patients with isolated DVT became asymptomatic, whereas patients with extended DVT (EDVT) remained symptomatic during follow-up in the post-DVT period (Table 5). Reflux, obstruction, or a combination of the two were more common in extended proximal EDVT with occlusive thrombosis in two or more segments of the leg vein than in isolated thrombosis in one segment of the leg vein. In this study, recurrent DVT and PTS skin damage were more likely to develop in EDVT than in those with DVT in a single vein segment. Patients with reflux and obstruction presented with more skin damage than those with reflux or obstruction alone. DVT extending from the calf vein to the proximal femoral veins produced the highest PTS prevalence (Table 5).

A recent multicenter, randomized, placebo controlled trial was conducted to assess active versus placebo MECS used for 2 years to prevent PTS after a first event of proximal DVT. From 2004–2010, 410 patients were randomly assigned to receive active MECS and 396 placebo stockings (PS). The primary outcome (Ginsberg’s criteria) was first assessed at 6 months post-DVT and at subsequent visits every 6 months thereafter. Ginsberg’s objective criteria included ipsilateral pain and swelling of at least 1 month’s duration, which are typical in overt PTS (worse at the end of the day, or with prolonged sitting or standing, and better after a night’s rest and leg elevation). The cumulative incidence of PTS at 2 years was 14.2% in active MECS versus 12.7% in PS (hazard ratio: 1.13; 95% CI: 0.73–1.76; P=0.58). The secondary outcome of symptomatic PTS according to the subjective Prandoni or Villalta criteria (Table 3) was first assessed at 6 months post-DVT and at subsequent visits every 6 months thereafter for 2 years. The cumulative incidence of PTS according to the subjective clinical criteria (Villalta clinical score ≥5 or ulcer at or after the 6 months subsequent visits for 2 years) was 52.6% in active MECS versus 52.3% in PS (hazard ratio: 1.00; 95% CI: 0.81–1.24; P=0.96). This result is similar to that found in the control arm of the Prandoni study. According to Aschwanden et al, in symptomatic post-DVT patients (CEAP 1–3 without a skin lesion and no anticoagulation)
with obstruction and/or reflux on DUS, it was clearly shown that MECS will not prevent DVT recurrence 6 months post-DVT, and that the effect of MECS on PTS symptom reduction are observed after a long-term follow-up of more than 5 years in females but not in males.

The European approaches to DVT and PTS

Objective measurement of PTS according to CEAP – and of reflux and the degree of recanalization on DUS – at 3 months and 6 months post-DVT is mandatory in evaluating the main

Study arm 1: no PTS
Recanalization and no reflux: no stockings
Study arm 2: reflux, venous pressure normal
No PTS: MECS versus no MECS
Study arm 3: PTS
Reflux, increased venous pressure → MECS
After 2 years: CEAP 1–2 no MECS
Study arm 4: PTS
Obstruction = No recanalization
Reflux, no reflux → MECS
CEAP 3–4 MECS

Notes: Study arm 1: Rapid recanalization, no reflux, and no PTS at 3 months post-DVT obviates the need to wear stockings and be treated with anticoagulation at 6 months post-DVT. Study arms 3 and 4: Delayed recanalization and/or, reflux on DUS and very early signs of PTS dictates the need for extended (even lifelong) anticoagulation to prevent DVT recurrence as the cause of PTS progression. Study arm 2: Complete recanalization, but reflux on DUS and no PTS (CEAP 0), which may indicate that compensated reflux has a normal ambulatory venous pressure due to an intact calf vein pump (the 2007 Neumann concept, as interpreted by Michiels et al⁴⁷–⁴⁹).

Abbreviations: DVT, deep vein thrombosis; MECS, medical elastic stockings; PTS, postthrombotic syndrome; CEAP, Clinical–Etiology–Anatomic–Pathophysiological; DUS, duplex ultrasonography.

Study arm 3: PTS at 6–12 months
Reflux, increased venous pressure → stockings
Study arm 4: 10% obstruction = No recanalization
Reflux, no reflux → MECS

Notes: At the time that the termination of regular anticoagulant treatment is or may be indicated, the discontinuation of oral anticoagulation should follow the D-dimer strategy of the PrOlOng and DULCIS studies.³³³ Rivaroxaban (Bayer, Leverkusen, Germany); Apixaban (Pfizer, New York City, NY, USA).

Abbreviations: DVT, deep vein thrombosis; MECS, medical elastic stockings; PTS, postthrombotic syndrome; NOAC, novel oral anticoagulants; CEAP, Clinical–Etiology–Anatomic–Pathophysiological.
determinants for PTS and DVT recurrence in a prospective safety outcome study, according to the proposed study designs shown in Figures 5–7. The rationale is based on the demonstration of a relationship between persistent RVT and the risk of VTE recurrence in two prospective studies.11,28 In one study,11 RVT at 3 months post-DVT was absent in 30% of post-DVT patients, which was associated with a very low recurrence rate of DVT of 1.2% during a 2-year follow-up period (score = 0 at 3 months; Table 4). The presence of RVT at 3 months post-DVT in two-thirds of post-DVT patients was associated with a high DVT recurrence rate of 27% during a 2-year follow-up period after the discontinuation of regular anticoagulation (score ≥3 or more; Table 4). The prospective study of 313 consecutive DVT patients RVT at any time post-DVT is a risk factor for recurrent VTE. In this study, repeated DUS of the common femoral and popliteal veins was performed at 3 months, 6 months, 12 months, 24 months, and 36 months post-DVT. The cumulative incidence of normal DUS (no RVT) was 39%, 58%, 69%, and 74% at 6 months, 12 months, 24 months, and 36 months post-DVT, respectively. Of 58 recurrent episodes of VTE, 41 occurred at the time of RVT. The hazard ratio for recurrent VTE was 2.4 for persistent RVT, as compared to complete vein recanalization.29

Palareti et al20,31,32 as well as subsequent studies, showed that DVT recurrence of about 5% per 100 patient year with normal D-dimer levels and 10%–15% per 100 patient years with increased D-dimer levels 1 month after discontinuation of anticoagulation. This difference was independent from other factors like thrombophilia or the presence or absence of RVT. Post-DVT patients with increased D-dimer levels after the discontinuation of anticoagulation belonged to the group of symptomatic post-DVT patients at high risk for developing PTS (score ≥3; Table 4). In the PROLONG study,30 extended anticoagulation in post-DVT patients with increased D-dimer levels reduced the risk of DVT recurrence from 11% of patients/year to <2% per 100 patient/year. In post-DVT patients with a normal D-dimer level, on the month after the discontinuation of regular anticoagulation, the incidence of DVT recurrence still increased to 4.4% patient/year. This implies that the segregation of low risk versus high risk of DVT recurrence by D-dimer levels alone in the PROLONG setting is specific but not sensitive enough. This may imply that DVT recurrence in those patients with either a normal or increased D-dimer very likely does occur in those with incomplete RVT and in complete RVT after 6 months with reflux score 3 or more (Table 4). This important observation has been confirmed by Latella et al34 in their prospective study of 305 DVT patients selected for quantitative ELISA D-dimer (VIDAS) measurements 4 months post-DVT. Of these 305 post-DVT patients, 46% developed PTS (according to the Villalta score); 25% developed mild PTS, 13% developed moderate PTS, 7% developed severe PTS, and 54% did not develop PTS during the 24-month follow-up period. Mean D-dimer levels measured 4 months post-DVT were significantly higher in patients with PTS versus those without PTS (712 µg/L versus 444 µg/L; *P*=0.02). At the time of D-dimer level measurement, 213 patients were treated with anticoagulants. Venous reflux assessment at 12 months in 116 patients moderate to severe PTS was present in 51%. Reflux was detected in 65% of patients with PTS compared to 43% of those without PTS, indicating that reflux on DUS is a minor relative risk, but it is not the only determinative factor, for PTS development.

The Maastricht study evaluated 125 consecutive DVT patients with confirmed proximal DVT (22% had a history of previous VTE), who were followed for 2 years using the Villalta clinical scores on four consecutive visits: 3 months; 6 months; 12 months; and 24 months post-DVT.35 After 6 months, patients with Villalta scores ≤4 in the absence of reflux on DUS were allowed to discontinue MECS therapy. If reflux was present, two consecutive scores ≤4 were needed to discontinue MECS therapy (asymptomatic compensated reflux, study arm 2; Figure 5). In the Maastricht study, MECS therapy was discontinued in 17% of patients at 6 months, in 48% at 12 months, and in 50% at 24 months.35 These observations are in line with those of the Brandjes et al.25 Prandoni et al26 and Kahn et al28 studies, obviating the need for MECS in

<table>
<thead>
<tr>
<th>N of limbs</th>
<th>CEAP 0–1</th>
<th>CEAP 2–3</th>
<th>CEAP 4</th>
<th>CEAP 5–6</th>
<th>Reflux obstruction</th>
<th>Recurring DVT</th>
</tr>
</thead>
<tbody>
<tr>
<td>41 IDVT</td>
<td>15</td>
<td>20</td>
<td>6</td>
<td>0</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>79 EDVT</td>
<td>10</td>
<td>40</td>
<td>21</td>
<td>8</td>
<td>61</td>
<td>16</td>
</tr>
<tr>
<td>71 symptomatic</td>
<td>10</td>
<td>40</td>
<td>21</td>
<td>8</td>
<td>61</td>
<td>16</td>
</tr>
</tbody>
</table>

Note: Symptomatic = symptomatic during a median follow-up of 3.4 years, indicating that half of IDVT and the majority of EDVT limbs become symptomatic for PTS according to the CEAP classification. Data from Labropoulos et al.25

Abbreviations: DVT, deep vein thrombosis; IDVT, isolated deep vein thrombosis; EDVT, extended deep vein thrombosis; CEAP, Clinical–Etiology–Anatomic–Pathophysiological; PTS, postthrombotic syndrome.
50% of post-DVT patients at 3–6 months post-DVT. In the Maastricht study, reflux on CUS was present in 74 of 101 (73.3%) tested patients. The cumulative incidence of PTS was 13.3% at 6 months, 17.0% at 12 months, and 21.1% at 24 months. Varicosity or venous insufficiency (present in 11% of patients at baseline) was significantly associated with PTS (hazard ratio: 3.2) range (1.2–9.1). In the Maastricht study, patients with a low probability for developing PTS could be identified at 6 months post-DVT. The results of the Italian and Dutch DVT–PTS studies indicated that DUS assessment 1 month, 3 months, and 6 months post-DVT was mandatory on top of objective PTS assessment according to CEAP score at 6 months, 1 year, and 2 years post-DVT, on the basis of which we designed the prospective clinical safety outcome study shown in Figures 5–7.

The role of MECS in the treatment of PTS

A clinical examination of the assessment of the risk on PTS by DUS should be performed in routine clinical practice at 3 months, 6 months, 1 year, and 2 years post-DVT to determine whether there is still a need for wearing MECS, and to see whether additional treatment is necessary (Figure 5).

About half of the DVT patients who have normal DUS 3 months post-DVT do not develop PTS after 3–9 months post-DVT; they do not need to wear MECS and anticoagulant can be stopped at 6 months post-DVT (Figures 5 and 6; Table 4). If no pathologic changes remain that means complete recanalization, and no reflux, the venous system functions normally and no PTS exists or will develop, the MECS do not need to be worn any longer and the asymptomatic patient can be discharged from the follow-up after 6 months (normal duplex Figure 5; Table 4). In the event that reflux of the deep venous system is found at and after 6 months post-DVT, according to extensive CDUS evaluation, additional strategies will mainly depend on the site and extension of RVO. If this involves only the femoral and/or popliteal veins and calf veins, continuation of MECS is advocated. If DUS raises suspicion only for residual obstruction at the inferior vena cava or iliofemoral level (with the absence of phasic flow at the level of the common femoral vein, visible obstruction of the external iliac vein, or prominent collateral circulation mostly crossing the pubis area), venography is performed.

Figure 7 Algorithm of the Rotterdam modification of the PROLONG study for the duration of anticoagulation and the compelling need to extend anticoagulant in post-DVT patients, preferentially with low doses of the Direct Xa (DOXa) inhibitors Rivaroxaban® 10 mg once daily; Apixaban® 2.5 mg twice daily, similar to what is done in the orthopedic surgical setting.

Notes: This algorithm is in accordance with the objective score assessment from, which has to be evaluated in prospective management studies in the primary care setting and in outpatient wards. Rivaroxaban (Bayer, Leverkusen, Germany); Apixaban (Pfizer, New York City, NY, USA).

Abbreviations: DVT, deep vein thrombosis; VKa, vitamin K agonist; nOac, novel oral anticoagulants; PTs, postthrombotic syndrome.
In most cases, puncture of the popliteal vein is used to access the deep venous system. Venous ulcers are treated according to modern evidence-based guidelines.38,39

DVT and PTS bridging the gap in prospective studies

In view of the proposed concept in Table 4 and Figure 5, four unanswered questions in the treatment of provoked and unprovoked DVT are:

1. Are 3 months and 6 months post-DVT the appropriate time points to determine the group of patients who do not have PTS and the group who do develop PTS? If yes, then this is to be demonstrated in a cost-effectiveness outcome study.

2. Which post-DVT patient has a clear indication for long-term compression therapy, so as to prevent PTS after the initial treatment in the acute phase of DVT? In symptomatic DVT and PTS legs to relieve symptoms with no or minor effect on DVT recurrence. To be evaluated in a prospective management study.

3. Can MECS and anticoagulation be safely discontinued at 3 months or 6 months post-DVT in the case of rapid recanalization, no reflux, and no PTS? If yes, then this is to be demonstrated in a cost-effectiveness outcome study.

4. Is the continuation of MECS and the extension of anticoagulation mandatory in the event of reflux with or without PTS at 6 months, 12 months, and 24 months post-DVT indicated for the prevention of DVT recurrence and for the increase of PTS severity? If yes, then this is to be demonstrated in a cost-effective, safety outcome study.

The diagnostic work up of post-DVT patients should follow the Rotterdam approach to PTS, according to according to Michiels et al.37,47–49 for the indication of wearing stockings (Figure 5). To address these questions, we propose a prospective safety outcomes study with a follow-up period of 1–5 years (Figures 5 and 6). Patients with provoked or unprovoked DVT at the time of diagnosis were included. All DVT patients will (according to the standard) immediately receive anticoagulant and compression therapy. Objective documentation will consist of PTS score assessments and DUS, plus ambulant venous pressure measurements, in order to make a therapeutic decision at time points 1 month, 3 months, 6 months, 9 months, 12 months, and 24 months post-DVT (Figures 5 and 6). Based on these objective measurements and assessments of PTS, DVT patients will be risk stratified at 6 months post-DVT for the continuation or discontinuation of compression therapy with MECS and anticoagulation, according to the study design (Figures 5 and 6), followed by discontinuation when no evidence of reflux obstruction or PTS symptoms are present.

Complete recanalization within 1–3 months and no reflux is predicted to be associated with no PTS, obviating the need for anticoagulation and MECS at 6 months post-DVT according to Michiels et al.37–49 (Figures 6 and 7). On the other hand, delayed incomplete or complete recanalization at 6–9 months post-DVT is usually complicated by reflux due to valve destruction, thereby indicating the need to continue anticoagulant treatment and the need to wear MECS (Figure 6). Post-DVT patients with no PTS and rapid recanalization within 3 months, no reflux, and no PTS at 6 months post-DVT do not need to wear MECS, and anticoagulation can be discontinued at 6 months post-DVT.47–48 This strategy from study arm 1 is predicted to be cost effective and safe. Patients with delayed recanalization and reflux with or without RVT, but with no significant PTS (CEAP 1–3) 3–9 months post-DVT, while wearing MECS, are candidates for extended anticoagulation for at least 1 year or 2 years, and they should be reevaluated 1 year post-DVT (Figures 5 and 6).47–49 Symptomatic patients with PTS (identified by an increased Villalta score or CEAP 3–4) 6 months post-DVT are candidates for wearing stockings for symptoms relief at work and when walking in the daytime. Patients with PTS, according to both the subjective Villalta and objective CEAP scores in addition to DUS at 6–12 months post-DVT, should be treated with oral anticoagulants for 2 years, and they should be considered for extended or even lifelong anticoagulation with VKA or NOAC in combination with MECS (Figure 7).

As demonstrated by Palareti et al11 in the PROLONG study, proper extension of anticoagulation with VKA or NOAC is key for the prevention of DVT recurrence, as it is the best option to prevent DVT recurrence and reduce the severity of PTS. Michiels et al49 have already started a pilot study to test the feasibility of planning a multicenter prospective management and safety outcome study, according to the proposed concept shown in Figure 6, in the primary care setting. PTS is a chronic condition that affects the deep venous system, and it may extend to the superficial venous system of the legs in patients with a documented history of DVT, as discussed in our clinical review on bridging the gap between DVT and the PTS by Michiels et al.49

According to Iorio et al,50 in 2010, the acceptable expected rate of recurrent VTE after the discontinuation of anticoagulation in post-DVT patients with a first unprovoked DVT was <4% in the first year and <6.7% after 2 years with the
discontinuation of OAT and VKA. As an extension of the PROLONG study, Cosmi et al. performed the DULCIS (D-dimer and ultrasound in combination Italian study) to establish the optimal duration of anticoagulation for VTE in 988 evaluable DVT patients with a first unprovoked DVT. After at least 3 months of anticoagulation, D-dimer levels were measured and DUS was performed to measure RVT (RVT < 4 mm), and followed according to two main strategies. Firstly, if the D-dimer level was below the age- and sex-specific cut-off values for each of the different D-dimer assays used, then anticoagulation was stopped and the D-dimer levels were reassessed at 15 days, 30 days, 60 days, and 90 days. If at the period of at least 6 months post-DVT the D-dimer level remained below the cut-off point, anticoagulation was definitely stopped and patients were followed-up for 2 years. In the cohort of 109 post-DVT patients who refused OAT treatment, and who had at least one D-dimer measurement above the cut-off value, the incidence of major VTE was 8.8%, and distal DVT or SVT was 2.3% patient/years. In 506 (51%) of the 988 analyzed patients, all D-dimer levels were below the cut-off point at 3 months (90 days) after stopping anticoagulation. The incidence of VTE was 2.8%, distal DVT was 1.1%, and SVT was 2.3% patient/years. Secondly, if one of the D-dimer levels was above the cut-off value 3 months (90 days) after discontinuation, then anticoagulation was resumed. This cohort of 373 patients with increased D-dimer levels that fell above the age- and sex-adjusted cut-off levels received OAT for 2 years follow-up and only four VTE events (0.7% patient/years) were observed at the cost of 14 major bleedings (2.3% patients/years). These data may indicate that the upper limit of a normal D-dimer test in post-DVT patients with early PTS does not seem to be low enough for safe DVT recurrence prevention. The presence of HER signs in PTS in either leg (CEAP 3 or CEAP 4) a lower ELISA VIDAS D-dimer cut-off level of 250 ng/mL is recommended in unprovoked DVT for lowering the risk on DVT recurrence after anticoagulation discontinuation in post-DVT patients at 6 months post-DVT.

In the proposed prospective study design that aims to bridge the gap between DVT and PTS, in patients with a first DVT provoked by a transient reversible factor (for example, surgery or a recent trauma), or in those with a provoked DVT who have a low risk of recurrent VTE 3–6 months post-DVT, it was determined that OAT can safely be discontinued (study arm 1; Figures 5 and 6). The decision to extend and/or to continue OAT indefinitely after completing 6 months of anticoagulant therapy for proximal DVT in unprovoked DVT is one of the most important unanswered questions in VTE management in the REVERSE studies. The present critical appraisal of the literature is in line with the suggestion that the early signs of PTS, with persistent abnormalities on DUS at 6 months post-DVT, and elevated D-dimer levels after the discontinuation of OAT are the main independent predictors of DVT recurrence and embolic complications (VTE). The combined use of each of these important univariate or single predictors for recurrent VTE will be sufficient in segregating patients at 6 months post-DVT into low enough (<3% person/year) groups to provide clinicians and patients with the comfort to confidently discontinue OAT.

A complete and detailed work-up and follow-up – as proposed in Figures 6 and 7, which expand upon the results of the PROLONG and DULCIS studies – are a significant step ahead to bridging the gap between DVT and PTS. To realize such a prestigious project, a multidisciplinary team of primary care physicians, clinicians, phlebologists, vascular internists, and radiologists is mandatory when cooperating in conducting transparent prospective management studies, to improve risk stratification of provoked and unprovoked DVT patients at 6 months post-DVT, for the indication to extend anticoagulation for 2 years, and so well-defined PTS patients can be followed up for several years (or even throughout their lives). The Canadian VTE Study Group conducted a multicenter, prospective, cohort, clinical decision rule derivation of 646 patients with a first unprovoked VTE treated with OAT for about 6 months, and the patients were followed for recurrent VTE after OAT discontinuation. The PTS signs of HER (CEAP ≥3) appeared to make biological and clinical sense as important risk factors for DVT recurrence and embolic complications. The presence of HER, as assessed by subjective Villalta by clinicians and objective CEAP criteria by phlebologists, on top of CUS abnormalities by phlebologists or radiologists at time points 3, 6 to 12 months post-DVT (Figures 6 and 7), surely will be the strongest predictors of DVT recurrence and embolic complications.

In view of the incidence and distribution of acute DVT in the proposed study design in Figures 5, 6, and 7 will have significant therapeutic implications. Symptomatic patients with acute iliofemoral DVT and rapid extension of proximal DVT into the iliofemoral region are candidates for catheter-directed thrombolysis in the hands of DVT experts, as the risk of severe PTS by anticoagulation alone is irreversible and high. Recanalization of distal DVT in the calf and lower popliteal region is predicted to be rapid and complete, with no reflux on DUS and no PTS according to the CEAP classification, obviating the need to wear stockings.
and receive anticoagulation therapy at 6 months post-DVT. Delayed and incomplete recanalization in proximal DVT, as well as the presence of reflux due to valve destruction (irrespective of the degree of recanalization on DUS at 3–6 months post-DVT), is associated with a high risk of DVT recurrence and the development of symptomatic PTS. This indicates the need to wear MECS for the relief of symptoms, and to extend anticoagulation to prevent DVT recurrence as the main cause of PTS, preferentially with a low dose of NOAC.

Acknowledgments
The present report on the DVT–PTS Bridging the Gap study design was initiated and written by Dr Michiels in his position of Senior Investigator, Phlebology, at the Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands, in the period between January 1, 2007–December 31, 2013 in a joint venture with Dr HA Martino Neumann, Rotterdam, the Netherlands, and Dr Gualtiero Palareti, Bologna, Italy. This was an invited manuscript (Proceedings of the DVT–PTS Workshop, 2nd European Chapter Congress of the International Union of Angiology; Rome, Italy; September 29, 2013).

Disclosure
The authors report no conflicts of interest in this work.

References


